Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

The FDA’s approval of a new Alzheimer’s treatment — the first one in almost two decades — should have been a cause for celebration. Instead, it has become a scientific and financial mess.

Why it matters: Experts from all corners of the health care world fear the FDA’s decision will undermine medical standards, explode the federal budget and fill millions of desperate people with false hope.

  • And, worst of all, they worry it could cement a perverse set of incentives that will cause all of those problems to keep happening.

The backstory: The FDA’s decision to approve Aduhelm, a medication developed by Biogen, was controversial at the time, and the criticism has only gotten louder.

  • The evidence that the drug works is extremely thin. The FDA’s own statisticians said it didn’t meet the agency’s usual standards.
  • An outside advisory panel — whose advice the agency usually follows — recommended against approving the drug. Three members quit in protest after the FDA disregarded their recommendation; one of them called this “probably the worst drug approval decision in recent U.S. history.”

What they’re saying: “How would we feel if the advisory committee had recommended against approval of the COVID vaccine but then FDA went ahead and approved it?” Matt Eyles, CEO of America’s Health Insurance Plans, told Axios. “I think we’d be having another very different conversation.”

Between the lines: Millions of Alzheimer’s patients and families are desperate for any signs of a promising treatment. Empathy for that pain may have motivated the FDA to ease up on Aduhelm, some critics say.

  • But an ineffective drug may be worse than no drug at all — especially when that unproven drug costs $56,000 per year.
  • Medicare will likely spend tens of billions of dollars per year just on Aduhelm. Patients who receive it will also need additional care, like imaging scans. By some estimates, Aduhelm and related care together could easily cost the U.S. over $100 billion per year.

Aduhelm is not just another expensive drug.

  • The U.S. has seen plenty of expensive drugs before. And as the industry has fought attempts to regulate its pricing, its most persuasive argument has been straightforward: Breakthroughs are expensive.
  • Some critics were up in arms when hepatitis C drug Sovaldi launched in 2013 with a price tag of $84,000 for a full course of treatment. Sovaldi and its successor drugs, however, have been a cure for most patients. Even their high price tags have been cheaper than a lifetime of treatment.

Aduhelm is different because Aduhelm hasn’t been proven to work, and will not have been proven to work before millions of people start taking it.

  • Patients will likely take it for several years, and if it doesn’t provide any clinical benefit, it will simply add billions more to the financial and emotional costs that Alzheimer’s already extracts.

Beyond the cost, many also fear Aduhelm’s approval will only make the long and painful search for a treatment longer and more painful.

  • There is a risk of false hope: Many Americans simply won’t know, when a doctor prescribes this new Alzheimer’s drug they’ve been hearing about, that there’s actually very little reason to believe it will slow their loved ones’ cognitive decline.
  • “There might be unrealistic expectations in people’s minds that this is a cure for Alzheimer’s when it’s clearly not,” said Marc Gordon, a neurologist and Alzheimer’s researcher at Northwell Health in New York.

Scientists still don’t know for sure what causes Alzheimer’s. Aduhelm is based on one prominent but unproven theory. With that drug on the market, it’ll get harder to meaningfully explore other possibilities, some experts warn.

What’s next: Medicare could save some money by putting limits on its coverage of the drug, or it could reject coverage completely. If ongoing trials don’t yield any more evidence that Aduhelm works, the FDA can pull it from the market — although Biogen has up to nine years to submit confirmatory trial data.

The bottom line: If the FDA is going to start greenlighting more drugs simply because they might work, that could unleash a flood of expensive and unproven products.

  • One possible early sign: Eli Lilly announced Friday it will seek FDA approval for its own Alzheimer’s drug — which has not been proven to work.

Go deeper: Read our interview with Biogen executives

Go deeper

Oct 5, 2021 - Health

Taxpayers funded development of COVID-19 antiviral pill

Illustration: Rae Cook/Axios

The antiviral pill that showed promising results against severe COVID-19 was originally developed at Emory University with $35 million of taxpayer grants.

Why it matters: The federal government consequently owns rights to some of the molnupiravir's patents, which could factor into future purchasing agreements with Merck, which sells the drug.

Updated 1 hour ago - Sports

MLB headed for first lockout since '95 as deal expires

Baseball Commissioner Rob Manfred (L) and Major League Baseball Players Association executive director Tony Clark. Photo: Matt King/MLB via Getty Images

Major League Baseball's collective bargaining agreement expired at 11:59 p.m. ET Wednesday without a new deal in place.

Why it matters: With no CBA, the MLB is headed for the first management lockout since a 1994-95 strike led to the cancelation of the World Series for the first time in 90 years.

Media giants back Bannon's bid to release Jan. 6 documents

Former Trump adviser Steve Bannon at the FBI Washington Field Office in Washington, DC., in November. Photo: Win McNamee/Getty Images

A coalition of news outlets including the Washington Post is supporting Stephen Bannon's campaign for the release of documents related to his contempt of Congress charges, WashPost confirmed Wednesday.

Why it matters: WashPost, the New York Times, CNN, NBC, the Wall Street Journal's parent company and others filed a motion arguing that a proposed protective order seeking to prevent the documents from being released violates the First Amendment, per the Daily Mail, which first reported on the news.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!